Redmond Asset Management LLC Sells 500 Shares of Simulations Plus, Inc. (NASDAQ:SLP)

Redmond Asset Management LLC reduced its stake in shares of Simulations Plus, Inc. (NASDAQ:SLP) by 2.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 18,770 shares of the technology company’s stock after selling 500 shares during the quarter. Redmond Asset Management LLC owned about 0.09% of Simulations Plus worth $523,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in SLP. Barclays PLC grew its stake in shares of Simulations Plus by 390.6% during the third quarter. Barclays PLC now owns 28,473 shares of the technology company’s stock valued at $911,000 after buying an additional 22,669 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Simulations Plus by 4.4% during the third quarter. Geode Capital Management LLC now owns 448,618 shares of the technology company’s stock valued at $14,367,000 after buying an additional 18,924 shares during the last quarter. State Street Corp grew its stake in shares of Simulations Plus by 4.7% during the third quarter. State Street Corp now owns 640,303 shares of the technology company’s stock valued at $20,503,000 after buying an additional 28,953 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Simulations Plus by 106.0% during the third quarter. JPMorgan Chase & Co. now owns 47,365 shares of the technology company’s stock valued at $1,517,000 after buying an additional 24,371 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its stake in shares of Simulations Plus by 402.9% during the third quarter. BNP Paribas Financial Markets now owns 39,944 shares of the technology company’s stock valued at $1,279,000 after buying an additional 32,002 shares during the last quarter. 78.08% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, Director Walter S. Woltosz sold 20,000 shares of the stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $33.91, for a total transaction of $678,200.00. Following the completion of the sale, the director now owns 3,402,584 shares in the company, valued at approximately $115,381,623.44. This represents a 0.58 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 19.40% of the stock is owned by company insiders.

Simulations Plus Stock Down 0.2 %

Simulations Plus stock opened at $31.77 on Friday. The business has a fifty day moving average of $31.71 and a two-hundred day moving average of $32.12. The firm has a market cap of $638.32 million, a P/E ratio of 79.43 and a beta of 0.83. Simulations Plus, Inc. has a twelve month low of $24.00 and a twelve month high of $51.22.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. Stephens assumed coverage on Simulations Plus in a research note on Friday, November 15th. They issued an “overweight” rating and a $39.00 price objective on the stock. KeyCorp increased their price objective on Simulations Plus from $35.00 to $37.00 and gave the stock an “overweight” rating in a research note on Friday, January 24th. William Blair reissued an “outperform” rating on shares of Simulations Plus in a research note on Wednesday, January 8th. Finally, StockNews.com cut Simulations Plus from a “hold” rating to a “sell” rating in a research note on Monday, November 4th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $49.40.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.